Equity Overview
Price & Market Data
Price: $1.00
Daily Change: +$0.079 / 7.90%
Range: $0.87 - $1.01
Market Cap: $16,813,700
Volume: 525,418
Performance Metrics
1 Week: -6.54%
1 Month: -18.03%
3 Months: -11.50%
6 Months: -4.76%
1 Year: 16.96%
YTD: -12.28%
Company Details
Employees: 5
Sector: Health technology
Industry: Pharmaceuticals: other
Country: United States
Details
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.